The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

Final rule makes it easier for CMS to suspend agents and brokers who exchange plans without notifying the Medicare customer.

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of

In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan year.

The Centers for Medicare & Medicaid Services Jan. 10 proposed a 4.3% payment increase to Medicare Advantage plans for calendar year 2026, amounting to approximately $21 billion. CMS also proposed to complete its implementation of a three-year phase-in of ...

The Biden administration’s last MA rule is a boon for insurers, though it remains to be seen how the incoming Trump administration might put its stamp on the regulation before it’s finalized this spring.

The CMS said 24.2 million people signed up during the enrollment window, including 3.9 million new enrollees. That's more than double the number of people who enrolled during the 2021 sign-up period, according to the announcement.

Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

The U.S. health agency, the Centers for Medicare & Medicaid Services (CMS), announced Tuesday that it will appeal a November 2024 ruling to the Fifth Circuit Court of Appeals. What Happened: In October,

My advice to clients who are new to Medicare is to begin searching for medical providers that are accepting Medicare, especially when a serious health issue is involved.